[공지사항]을 빙자한 안부와 근황 
Show more

Daily Arxiv

This is a page that curates AI-related papers published worldwide.
All content here is summarized using Google Gemini and operated on a non-profit basis.
Copyright for each paper belongs to the authors and their institutions; please make sure to credit the source when sharing.

A PBN-RL-XAI Framework for Discovering a “Hit-and-Run” Therapeutic Strategy in Melanoma

Created by
  • Haebom

Author

Zhonglin Liu

Outline

In this paper, we construct a dynamic probabilistic Boolean network model to understand the molecular network underlying innate resistance to anti-PD-1 immunotherapy in metastatic melanoma, systematically discover optimal multi-step therapeutic interventions using reinforcement learning agents, and mechanically interpret the agent’s control policy using explainable artificial intelligence. Our results reveal that precisely timed, four-step transient inhibition of lysyl oxidase-like 2 protein (LOXL2) is the most effective strategy. Explainable analysis shows that such “hit-and-run” interventions are sufficient to erase the molecular signatures that drive resistance, and that the network can self-correct without continuous intervention. This study presents a novel time-dependent therapeutic hypothesis for overcoming immunotherapy resistance and provides a powerful computational framework for identifying unclear intervention protocols in complex biological systems.

Takeaways, Limitations

Takeaways:
A novel time-dependent therapeutic strategy (transient inhibition of LOXL2) to overcome anti-PD-1 immunotherapy resistance is presented.
Provides a powerful computational framework for discovering optimal therapeutic interventions in complex biological systems.
Interpreting the mechanisms of therapeutic effects using explainable artificial intelligence.
Limitations:
Currently, this is a hypothesis based on a computational model and needs to be verified through in vivo or clinical trials.
Further validation of the model's accuracy and generalizability is needed.
Further studies are needed on the long-term effects and side effects of LOXL2 inhibition.
Further studies are needed to determine generalizability across different cancer types and patient populations.
👍